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The R132H mutation of cytosolic isocitrate dehydrogenase (IDH1) is present in the majority of low grade gliomas.
Immunotherapy in these tumors has an interesting, still unexploited, therapeutic potential, as they are less
immunosuppressive than glioblastomas.
Using site-directed mutagenesis we introduced the R132H mutation into the murine glioma cell line GL261,
creating mIDH1-GL261. Presence of the mutation was confirmed by immunoblotting and production of the
oncometabolite 2-hydroxyglutarate (2HG), demonstrated by mass spectrometry (LC-MS/MS) performed on cell
supernatant. In vitro mIDH1-GL261 had different morphology but similar growth rate than parental GL261
(p-GL261). After intracranial injection, MRI suggested that the initial growth rate was slower in mIDH1-GL261 than
p-GL261 gliomas but overall survival was similar. mIDH1-GL261 gliomas showed evidence of R132H expression and
of intratumoral 2HG production (evaluated by MRS and LC-MS/MS). Immunizations were performed nine days after
intracranial implantation of mIDH1- or p-GL261 cells by three subcutaneous injections of five different peptides
encompassing the IDH1 mutation site, all emulsified with Montanide ISA-51, in association with GM-CSF. Control
mice were injected with four ovalbumin peptides or vehicle. Mice with mIDH1-GL261 but not p-GL261 gliomas
treated with mIDH1 peptides survived longer than controls; 25% of them were cured. Immunized mice showed
higher amounts of peripheral CD8+ T cells, higher production of IFN-γ, and evidence of anti-mIDH1 antibodies.
Immunizations led to intratumoral up-regulation of IFN-γ, granzyme-b and perforin-1 and down-regulation of
TGF-β2 and IL-10.
These results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1
mutations.
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The new era of cancer genomics, due to the revolution
of next generation sequencing, was heralded in 2008 by
the discovery of mutations in the IDH1 gene in glioblast-
omas (GBM) [1]. Subsequently it was found that IDH1
mutations are present in the large majority of low grade
gliomas (LGG) and define secondary GBM more rigorously
than before [2]. Remarkably, a new function of IDH1 was
found as a consequence of the R132H mutation that affects
the active site of the enzyme [3]. IDH1, that normally* Correspondence: gaetano.finocchiaro@gmail.com
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unless otherwise stated.catalyzes the production of alpha-ketoglutarate (alpha-KG),
in its mutated form released 2-hydroxyglutarate (2HG),
subsequently defined as an oncometabolite [3]. Mutations
of the cytosolic IDH1, as well as of the mitochondrial
isoform IDH2, were subsequently found in other tumors
like cholangiocarcinomas [4], leukemias [5] and others,
reviewed in [6]. In gliomas, one main consequence of the
R132H mutation is the alteration of the epigenetic pat-
terns, as 2HG may act as a competitive inhibitor of histone
and DNA demethylases requiring alpha-KG as a cofactor
[7-9]. Initially, increased neo-angiogenesis due to increased
expression of the pro-angiogenic factor HIF-1α was also
found as a consequence of IDH1 mutation [10].
Due to mutation frequency and importance of the
modulation of glioma biology, an increasing effort hasral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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IDH1. New drugs that are acting on the novel function of
IDH1 are under development and are initially tested in
patients [11]. Furthermore, the diagnosis of the mutation
in peripheral blood as well as the detection of increased
levels of 2HG by MRI in the brain are actively pursued
and initial results are available [12,13].
As in the case of EGFRvIII, the R132H mutation cre-
ates a novel, cancer-specific epitope, that could be po-
tentially targeted by immunotherapy, as recently shown
by Schumacher et al. [14]. This could be particularly ef-
fective in LGG as these tumors, due to their association
with longer survival than GBM [15] and with a less im-
munosuppressive microenvironment [16], may offer a
wider window for the development of a therapeutically
meaningful immune response. To this goal we have de-
veloped a glioma model of the R132H mutation that is
immunologically actionable. Our results suggest that
peptide vaccination may delay and, in a fraction of cases,
cure an intracranial glioma that is otherwise lethal in
about one month.
Materials and methods
Generation of GL261-IDH1-R132H cell line
Site directed mutagenesis was performed on pCMV6kan-
neo vector containing the murine wild-type IDH1 cDNA
(NM_010497.3) (Origene, Rockville, MD, USA), human
IDH1mutation R132H was introduced (see Additional
file 1).
GL261 adherent cells were seeded in 6-well plates at
2 × 106 cells per well 24 hours prior to the transfection.
Cells were transfected with 10 μg of empty or IDH1-
R132H– DNA vector using Lipofectamine 2000 Transfec-
tion Reagent (LifeTechnologies), according to the manufac-
turer’s instructions. Twenty-four hours after transfection,
GL261 cells were split and grown in fresh medium contain-
ing 0.5 mg/ml of G418 (Lonza) as selective agent.
Parental and IDH1-GL261 were grown in DMEM, 1X
Pen Strep,1X L-glu, 20% Fetal Bovine Serum (LifeTechnol-
ogies). The cell Proliferation Reagent WST-1 (Roche) was
used to measure proliferation plating 3000 cells/well. Six
replicates per point were analyzed.
Peptide prediction
Mice were immunized with two 9-mer (PEP1 - IDH1-
R132H126–134: KPIIIGHHA; PEP2 - IDH1-R132H128–136:
IIIGHHAYG), two 10-mer (PEP3 - IDH1-R132H131–140:
IGHHAYGDQY; PEP4 - IDH1-R132H123–132: GWVKP
IIIGH) and a 16-mer (PEP5 - IDH1-R132H126–141: KPIIIG
HHAYGDQYRA) peptides spanning the IDH1 mutation.
Negative control peptides were: OVA155–62: KVVRFDKL;
OVA2107–114: AEERYPIL; OVA3176–183: NAIVFKGL,
synthesized by Primm srl (Milano), and OVA4257–264:
SIINFEKL (Sigma Aldrich).In vivo treatments
Five week-old females C57BL/6N mice (Charles River
Laboratory, Calco-Lecco Italy) were injected with 50,000
pGL261 cells (n = 44) or mIDH1-GL261 (n = 80). A total
of 24 mIDH1-GL261 glioma bearing mice were sacri-
ficed after second immunization for immunological and
histological studies (6 mice per group of treatment). The
stereotactic coordinates with respect to the bregma
were: 0.7 mm posterior, 3 mm left lateral, and 3.5 mm
deep, into the nucleus caudatum. Glioma-bearing mice
were treated using four different conditions: group I:
vehicle only (GM-CSF and Montanide); group II: three
immunizations spaced one week apart (days 9, 16 and
23) with two 9-mer and two 10-mer peptides; group III:
three immunization spaced one week apart (days 9, 16
and 23) with the 16-mer peptide; group IV: ova peptide
immunizations. Single peptides (15 μg/peptide) were
emulsified with Montanide ISA-51 VG (1:1; SEPPIC) as
previously described [17,18], and administered by sub-
cutaneous injections of the 16-mer peptide (group III)
or the four peptides separately (group II and group IV)
into different areas of the flank. The immunized mice re-
ceived a total of 3 μg of recombinant murine granulocyte
macrophage colony-stimulating factor (GM-CSF) (Miltenyi
Biotec) spread out over three injections into the same area
of the peptide injections, beginning one day before the first
vaccination.
Animal experiments were performed in accordance to
the Italian Principle of Laboratory Animal Care (D. Lgs.
26/2014) and European Communities Council Directives
(86/609/EEC and 2010/63/UE).
Isolation and characterization of splenocytes
Splenocytes from immunized and control mice were
isolated after the second immunization. Before staining,
splenocytes were grown in RPMI 1640 (EuroClone) con-
taining 10% heat-inactivated fetal bovine serum (FBS)
(Life Technologies), 100 U/mL penicillin (EuroClone),
100 U/mL streptomycin (EuroClone), 100 μg/mL glu-
tamine (EuroClone), 0.1 mM non-essential amino acids
(EuroClone), 1 mM sodium pyruvate (EuroClone), 50 μM
β-mercaptoethanol (EuroClone) and 10 U/mL IL-2
(Miltenyi Biotec). Cells were stimulated for 4 h with
0.25 μM ionomycin and 10 ng/mL phorbol myristate
acetate (PMA) and 2 hours with 10 μg/ml brefeldin
A. A total of 1.5 × 106 cells were stained in PBS 1X/
0.5% bovine serum albumin/2 mM EDTA for 10 min
at 4°C with the following antibodies (Miltenyi Biotec):
anti-CD3 Vioblue; anti-CD4-APC, anti-CD8-PE-Vio770,
anti-CD62L-FITC and anti-CD49d-PE for T cell detection.
The cells were then fixed and permealized using the
Miltenyi Biotec Inside Stain Kit and intracellularly stained
according to the manufacturer’s instructions with IFN-γ-
PE or APC (Miltenyi Biotec). The CD8 +CD3+; CD3 +
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try for IFN-γ production and for the evaluation of CD62L
and CD49d expression. Flow cytometry acquisition was
performed on a MACSQuant instrument, and the data
were analyzed with the MACSQuantify Software (Miltenyi
Biotec).
Cytotoxic and proliferation assays
Lymphocytes from immunized and control (vehicle and
ova-treated) mice were isolated after second immuni-
zation. A total of 2 × 106 splenocytes were pre-stimulated
for 5 days in the presence of 5 × 105 irradiated (3-Gy),
naïve splenocytes, acting as antigen presenting cells, and
10 μg/mL of each peptide. Pre-stimulated splenocytes
were tested for GL261-specific cytotoxicity using 10:1,
20:1 and 40:1 effector:target (E:T) ratios. The cytotoxic
MTT assay was performed according to the manu-
facturer’s instructions (Millipore). For proliferation assay,
2 × 106 splenocytes were primed for 4 days in the presence
of 5 × 105 naïve splenocytes that had received 3 Gy irradi-
ation, 10 μg/mL of IDH1 mutated or OVA peptides and
10 U/ml of IL-2. After pre-stimulation, 5 × 105 splenocytes
were incubated for 20 h in the presence of single peptides
(10 μg/ml) and 10 U/ml IL-2 and tested for their ability to
proliferate using MTT Reagent (Millipore). The data are
expressed as the percentage of proliferation, calculated
according to the following equation: (OD stimulated
splenocytes – OD splenocytes without peptide)/OD
stimulated splenocytes × 100.
IgG ELISA
ELISA plates were coated with 0.01 mg/ml IDH1 R132H
peptides for IgG detection in sera of immunized and
control mice. Ovalbumin peptides were used as peptide
coating control. The plate was washed and blocked with
PBS 10% FCS for 2 h at room temperature. The plate
was washed and mouse sera (1:100) were incubated for
2 h at room temperature. After washing the plate, HRP-
conjugate secondary antibody IgG-HRP (1:5000) was
incubated for 1 h in the dark at room temperature. The
plate was washed and incubate with tetramethylbenzi-
dine (TMB) and the reaction was stopped with H2SO4
1 M. OD at 450 nm was measured.
Real-time PCR (RT-PCR)
Total RNA was isolated from freshly harvested GL261
gliomas and lymphocytes from immunized and control
mice and used for gene expression analysis. RNA was
extracted with TRIzol reagent (Life Technologies) using
the RNeasy MINI KIT (Qiagen) and the RNase-Free
DNase Set (Qiagen). cDNA was synthesized from total
RNA using oligo (dT) and M-MLV Reverse Transcript-
ase (Life Technologies). Specific primers for target genes
were designed for Fast SYBR Green chemistry (LifeTechnologies) and purchased from Primm S.r.l. The
relative mRNA levels were evaluated using a ViiA-7
Real-Time PCR System (Life Technologies) and calcu-
lated using the ΔΔCt method. The expression levels of
the target genes were normalized to the expression level
of beta-actin (see oligo sequences in Additional file 1).
Western blot
Total proteins were isolated using tissue lysis with PK
buffer (NaH2PO4 0.2 M; Na2HPO4 0.2 M; NaCl 5 M;
EDTA) and protease inhibitor buffer (Triton 100X 2%;
SDS 0.25%; Leupeptin 0.90%; Pepstatin A 0.90%; PMSF
0.90%), and centrifuged to pellet debris. Protein concen-
trations were measured by Micro BCA protein assay kit
(Thermo Scientific) at 540 nm. Proteins (20 μg) were
diluted in NuPAGE® LDS Sample Buffer 4X (Invitrogen)
and NuPAGE Reducing Agent 10X (Invitrogen) and elec-
troblotted onto nitrocellulose membranes at 30 Volts for
1 h . Membranes with transferred proteins were incubated
with the primary antibody anti-IDH1-R132H (1:100,
Dianova) or anti-vinculin (1:5000, Abcam, Cambridge,
UK). The primary antibody incubation was followed
by incubation with the secondary antibody anti-mouse
(1:10000). A chemiluminescence reaction using the ECL
(enhanced chemiluminescence) Plus kit (Amersham, GE
Healthcare) was detected using film.
Liquid chromatography (LC-MS/MS) and magnetic resonance
spectroscopy
Tumour lysates (100 μL) were denatured by adding
10 μL of thrichloroacetic acid (TCA) 1 M containing
2HG-d3 (130 μM) as internal standard. After mixing
and centrifugation, the supernatants were analyzed for
2-hydroxyglutaric (2HG) determination using an Ultra
High Pressure Liquid Chromatography system (UPLC®,
Waters) coupled with a triple quadrupoles mass spec-
trometer (TQD, Waters) operating in multiple reaction
monitoring mode (MRM). Protein normalization was
obtained using the microBCA kit (Thermo Scientific).
Supernatants were obtained from a sub-confluent cell
cultures (3 × 106 cells).
MRI/MRS studies were performed on a 7 Tesla BioS-
pec 70/30 USR scanner equipped with a 12 cm inner
diameter actively shielded gradient system reaching a
maximum amplitude of 400 mT/m. (Bruker BioSpin,
Ettlingen, Germany). T2-weighted images were acquired
in three orthogonal (axial, sagittal, and coronal planes)
using a rapid acquisition with relaxation enhancement
(RARE) sequence (TR/TE = 3000/13 ms, matrix size =
256 × 256, RARE factor = 8, slice thickness = 0.7 mm,
FOV = 2 × 2 cm2, in plane resolution = 78 μm, number
of averages(NA) = 1, acquisition time (AT) = 1 min 30 s).
1H spectra carried out by two PRESS sequence with
different Echo Time (TE) TE =13 ms and 50 ms
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justment of the first and second order shims conducted
beforehand by Mapshim macro of Paravision 5.1 software)
from a single voxel (~10 μL) located inside a tumor (or,
before detecting solid tumor, at the injection site). The
spectra were analyzed with LCModel software (Version
6.3) [19] for metabolites absolute quantification. The me-
tabolites concentration for each single mouse at different
time point (before, one week, twenty days and one month
after the tumor cells injection) are presented as absolute
concentration ± CRB error [20]. The metabolites with
CRB error less than 20% of the estimated metabolite con-
centration were considered. Also the relative concentra-
tion with respect to Creatine is reported.
Histology and immunohistochemistry
For histology of murine gliomas, brains were carefully re-
moved, post-fixed in 4% paraformaldehyde, and embedded
in paraffin. Five μm thick sections were dissected using a
microtome. IHC analysis for IDH1-R132H was performed
on paraffin-embedded sections using the anti-IDH1-R132H
antibody (Dianova). The paraffin was removed using xylene,
and the sections were rehydrated in graded alcohol.
Antigen retrieval was carried out using preheated tar-
get retrieval solution (pH 6.0), and the primary anti-
bodies were incubated overnight. Single immunostains
were performed using a standard immunoperoxidase
protocol (Vectastain Elite ABC kit, PK-6100; Vector
Laboratories, Inc., Burlingame, CA, USA) followed by a
diaminobenzidine chromogen reaction (Peroxidase sub-
strate kit, DAB, SK-4100; Vector Lab). All sections were
counterstained with Mayer’s hematoxylin and visualized
using a LEICA MDLB light microscope.
Statistical analysis
Statistical comparisons of the data sets were performed
using a two-tailed Student’s T-test, and the results were
considered significant at p < 0.05. Cumulative survival
curves were constructed using the Kaplan-Meier method
(MedCalc 9.3).
Results
GL261-cells overexpressing IDH1-R132H produce 2HG and
are tumorigenic in vivo
To verify the potential effects of IDH1 mutation on
tumor progression, we over-expressed IDH1-R132H in
GL261 cells creating mIDH1-GL261. Expression of mIDH1
mRNA was detectable by RT-PCR in mIDH1-GL261
15 days after selection with G418, and highly increased on
day 24 after transfection (Figure 1a). Accordingly, expres-
sion of the mutant protein was clearly observed from day
15 by Western blot with R132H mutation specific anti-
bodies (Figure 1b). At the same time point mIDH1-GL261
cells appeared smaller that pGL261 and with fibroblast-likefeatures (Figure 1c). No significant difference in prolifera-
tion was visible in vitro, as evaluated at four time points
(24, 48, 72 and 96 h, Figure 1d). mIDH1-GL261 released
2HG in micromolar amounts in the culture medium, as
measured by LC-MS/MS (Figure 1e).
The overall survival of mice injected intracranially
with mIDH1-GL261 cells appeared initially longer than
in pGL261 controls, but the two curves merged later
(Figure 1f ). Observations on tumor size by MRI were co-
herent with survival data. Eight days after implantation, in
both groups no signal alteration on T2-weighted (wi) im-
ages was evident along the injection track (Figure 1g). On
day 20 the tumor onset was detected as a bright area on
the T2-wi images. pGL261-gliomas were growing more
rapidly than mIDH1-gliomas but remained small and
circumscribed (Figure 1h). Thirty days after tumor cell in-
jection, the mIDH1-GL261 gliomas were still smaller but
brighter than pGL261 gliomas (Figure 1i). By RT-PCR on
explanted gliomas we found that the expression of IDH1
was significantly reduced over the time, from 48.8 ± 1.3 on
day 20 to 24. ± 0.4 on day 30 (p < 0.001) (Figure 1l).
Histology with H&E staining showed that pGL261-
gliomas were characterized by pleomorphic and mitoti-
cally active cells, while mIDH1-gliomas were composed
of single small and round cells occasionally organized as
cell nodules (Figure 1m). Immunostaining with specific
antibodies confirmed the expression of IDH1-R132H in
gliomas originating from mIDH1-GL261, but not in
pGL261 gliomas (Figure 1n).
mIDH1-GL261 gliomas maintain 2HG production
In order to evaluate the absolute concentration of 2HG,
magnetic resonance spectroscopy (MRS) was performed
on mice before and after (on day 8 and 20) pGL261 or
mIDH1-GL261 implantation. A preliminary optimization
of 2HG detection was performed by acquiring sequences
with two different Echo Time values: TE = 13 ms and
TE = 50 ms for each examination session (not shown). A
more accurate quantification was obtained using spectra
with the shorter TE, as also previously described [21]. In
pre-injection MRS data, there was no evidence of 2HG
in all the examined animals (Figure 2a and b, left panels;
quantification in Figure 2c). The improved signal-to noise
ratio and the use of quantitative standards allowed to
obtain for the first time an absolute quantification of 2HG
in mouse brain. On day 8 mIDH1-GL261 gliomas showed
a significantly higher concentration of 2HG as compared
to pGL261 gliomas (4–7 mM vs 2 mM, Figure 2c and a, b
right panels). Interestingly an accumulation of 2HG higher
than the background was also reported in a subgroup of
human wild type IDH gliomas [22]. Decreased concen-
tration of 2HG was detected on day 20 (Figure 2c). No
difference in the absolute concentration of the other me-
tabolites investigated was observed (e.g. choline, lactate,
Figure 1 mIDH1-GL261 cells release 2HG in vitro and are tumorigenic. a RT-PCR analysis shows that IDH1 expression was significantly higher
in mIDH1-GL261 compared to control cells. b Western blot analysis of IDH1-R132H expression in transfected GL261 cells after 15, 18 and 24 days
of selection. Compared to empty (control cells), the levels of IDH1-R132H are significantly increased. Vinculin was used as housekeeping protein.
c GL261 cells over-expressing IDH1-R132H selected for 24 days in the presence of G418 changed morphology compared to control cells. d Proliferation
of pGL261 and mIDHI-GL261 as shown by WST proliferation assay performed at four different time points. e mIDH1-GL261 released 2HG in the cell
supernatant as evaluated by LC-MS/MS. f mIDH1-GL261 when injected in vivo grew slower than control, however in the later stages the survival curves
overlapped (n = 8 mice/group, p = 0.36). g, h, i MRI T2-weighted images confirmed the slower engraftment of mIDH1-GL261 glioma-bearing mice com-
pared with controls at three different times. l RT-PCR performed on explanted gliomas shows that IDH1 overexpression was higher that controls at day
20 and begins to decrease 30 days after tumor implantation. m, n Representative IHC shows the expression of IDH1-R132H in gliomas from mIDH1-
GL261 compared to control pGL261-gliomas where expression of IDH1 mutation was totally absent.
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sured by LC-MS/MS in gliomas explanted on day 30, con-
firming the presence of millimolar levels of the metabolite,
with higher expression in the mIDH1-GL261 (Figure 2d).
mIDH1-GL261 gliomas appeared macroscopically more
hemorrhagic than pGL261-gliomas and showed increased
levels of HIF-1α and VEGF (Additional file 2: Figure S1)
[10,23].
Immunization with mutated IDH1 peptides significantly
increases survival inducing specific cytotoxic and
antibody responses
To determine whether IDH1-R132H could be a target
for glioma immunotherapy we treated mIDH1-GL261
glioma-bearing mice with four short peptides (two 9-mers
and two 10-mers) or one 16-mer peptide, all encompass-
ing the IDH1 region encoding the mutation. Vaccinations
with peptides were performed on days 9, 16, and 23 after
tumor implantation (Figure 3a). Peptide immunizations
significantly increased survival as compared with vehicle-treated and ovalbumin (ova) peptide-treated controls
(Figure 3b). Immunization of pGL261-glioma-bearing
mice using the same peptides was ineffective (Figure 3c),
demonstrating that the immune response induced by pep-
tide vaccines specifically targets mIDH1-expressing cells.
Immunogenicity and functionality of peptides used for
immunizations was assessed by an in vitro proliferation
assay (Figure 3d). Splenocytes from control (vehicle and
ova), or from immunized mice were stimulated using a
mixture of irradiated antigen presenting cells and pep-
tides. Four days later, single peptides were assessed for
the ability in inducing lymphocyte proliferation. Spleno-
cytes from immunized mice proliferated in the presence
of IDH- mutated peptides but not of ova peptides. PEP4,
in particular, induced 90% of proliferation. On the con-
trary peptides were unable to stimulate splenocytes from
“vehicle” mice. Splenocytes from ova-immunized mice
proliferated when in presence of one out of four peptides,
confirming the ability of this peptide to induce some cyto-
lytic response [24].
Figure 2 2HG concentration is higher in mIDH1-GL261 than pGL261-gliomas. a, b Representative spectra show variation of brain
metabolite concentration measured at the injection site of gliomas from mIDH1-GL261 compared to controls. Data were acquired before cell
injection (pre-injection), and 8 days after tumor implantation. c 2HG concentration increased in mIDH1-GL261 gliomas at day 8 and decreased on
day 20 possibly as a consequence of a decreased expression of IDH1 as evaluated by RT-PCR on explanted gliomas (Figure 1l). d Intratumoral
2HG measured at day 30 showed higher levels in mIDH1-GL261 than in pGL261-gliomas.
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response in spleens of immunized mice compared with
controls (Figure 3e). CD8+ T cells from mice immunizedwith four peptides produced higher level of IFN-γ and
lost CD62L expression indicating the effector phase of
the lymphocytes (Figure 3f ). They expressed higher
Figure 3 (See legend on next page.)
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Figure 3 Immunization with mutated IDH1 peptides prolongs survival and promotes specific anti-tumor responses. a Experimental
schema of in vivo treatments. Two groups or mice injected with mIDH1-GL261 or pGL261 were immunized with three subcutaneous vaccinations
on days 9, 16 and 23 after tumor implantation with four peptides (two 9-mer and two 10-mer), or with a single peptide (16-mer) emulsified in
Montanide (15 μg/single peptide). A total of 3 μg of GM-CSF/mouse were administered during each immunization. Two group of control mice
were treated with GM-CSF and Montanide alone or with ova peptides. On day 19 mice were sacrificed for immune monitoring. b, c Kaplan-Meier
curves show that immunized mIDH1-glioma mice (four peptides n = 12; 16-mer peptide n = 12) survived longer than control mice (vehicle, n = 12; ova
n = 12). Immunizations of p-GL261 glioma-bearing mice did not modify the survival. d Splenocytes from immunized mice proliferated significantly
more than splenocytes from control (vehicle and ova treated) mice in the presence of IDH1-R132H peptides, particularly of peptide 4 (*p < 0.01;
**p < 0.005; ***p < 0.001, ****p < 0.0001), not in presence of ova peptides. e Flow cytometry performed on splenocytes shows that CD8+ but not
CD4+ T cell percentage increased significantly in immunized mice compared to controls (n = 6 mice/group). No difference between vehicle and ova
peptide immunizations. Data are reported in dot plots as the mean%± SD. f Flow cytometry histograms show that CD3 + CD8+ T cells produced more
IFN-γ and expressed less CD62L and more CD49d than controls (vehicle and ova histograms were overlapped). g In vitro MTT cytotoxicity assay reveals
that splenocytes from immunized but not from control mice lyse mIDH1-GL261 cells. h Scatter plot shows mIDH1 specific IgG detected in serum from
mice immunized with four peptides. Single plots represent the mean of three serum samples/group.
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homing into the glioma (Figure 3f ) [25]. CD8+ T cells
from mice immunized with the 16-mer peptide showed
an intermediate expression of IFN-γ and two subpopula-
tions with high or absent CD62L expression, suggesting
the coexistence of both naïve and effector cells (Figure 3f).
Part of the splenocytes from immunized mice were pre-
stimulated with peptides and tested five days later for
cytotoxic ability using an MTT assay. The splenocytes
from mice treated with IDH1-R132H peptides displayed
specific cytotoxicity against mIDH1-GL261 compared
with vehicle and ova controls (Figure 3g), but not against
pGL261 (Additional file 2: Figure S2). IDH1-R132H spe-
cific IgG were detected in serum of mIDH1-GL261 glioma
bearing mice after immunization with the four peptides
compared with controls. No IgG response was found after
immunization with the single 16-mer peptide (Figure 3h).
Peptide immunizations modulate tumor microenvironment
specifically affecting mutated IDH1 expression
Gliomas from mice treated with vehicle maintained
highly vascularized features showing large and medium
size-vessels. In gliomas from immunized mice the number
of blood vessels was reduced (Figure 4a, b) and was simi-
lar to pGL261-gliomas (Additional file 2: Figure S1d).
HIF-1α and VEGF expression were significantly reduced
in gliomas from immunized mice compared with controls
(Additional file 2: Figure S3).
Vehicle gliomas appeared immune-reactive for IDH1-
R132H, whereas gliomas from immunized mice almost
completely lost IDH1-R132H expression (Figure 4c), as
also confirmed by RT-PCR (Figure 4d).
The immune response induced by peptide immuniza-
tions determined a significant modulation of tumor
microenvironment. IFN-γ, granzyme-b and perforin-1
expression levels were 2.6 ± 0.04, 3.2 ± 0.03- and 2.1 ±
0.02- fold higher, respectively, in immunized mice than in
vehicle mice (p < 0.01, p < 0.005, p = 0.01; Figure 4g). Incontrast, TGF-β2 and IL-10 expression levels were 2.4 ±
0.22- and 2.3 ± 0.01-fold lower, respectively, in immunized
mice than in control animals (p = 0.01 and p < 0.005;
Figure 4h).
Discussion
Recent data have shown that the most frequent IDH1
mutation, R132H, can be effectively targeted in a A2.
DR1 mice devoid of mouse MHC and transgenic for
human MHC class I and II [14]. The R132H mutation
was expressed in sarcoma cells obtained by exposure to
3-methylcholantrene that were injected subcutaneously
in the A2.DR1 mice [14]. Our results show for the first
time in an intracranial glioma model that the R132H
mutation, can be effectively targeted by the immune sys-
tem, allowing a significant prolongation of survival and
the cure of 25% of the mice. The mIDH1-GL261 model
we have used has obvious differences with human gli-
omas, as it is established in a malignant glioma while in
humans IDH1 mutations take place early in develop-
ment of low grade gliomas. An important similarity,
however, is that, as in the human counterpart, mIDH1-
GL261 cells produce increased amounts of the oncome-
tabolite 2HG in vitro and in vivo. Although at a much
lower level, pGL261 also release detectable amounts of
2HG. As mentioned in Results, levels higher than back-
ground were found in a subset of wild type IDH gliomas
[22]. Interestingly, 2HG production was also found in
breast cancer cells in association to MYC overexpression
[26]. This may also be the case of pGL261 cells, as they
show increased myc expression [27]. The presence of
the mutation is associated to a decreased growth in vivo,
exemplified by MRI scans taken on day 8 and 20 after
intracranial injection of tumor cells (Figure 1g, h) and by
the trend in Kaplan Meier survival curves until day 28
(Figure 1f ), even if differences with pGL261 were not
statistically significant. A recent research by Phillips and
colleagues may provide some explanation for this finding,
Figure 4 Immunization with peptides targets IDH1-R132H and modulates the tumor microenvironment. a, b H&E of representative
mIDH1-GL261 gliomas from vehicle and immunized mice confirms a strong vascularization an a higher presence of blood vessels in gliomas from mice
treated with vehicle. c Gliomas from immunized mice show a lower cell density and absence of mIDH1 expression. d RT-PCR shows IDH1 expression
in gliomas from control mice and a significant reduced expression in immunized mice. The relative expression of IDH1 was normalized with that
detected in gliomas from pGL261. e, f RT-PCR on explanted gliomas shows that IFN-γ, granzyme (gzm)-b and perforin (prf)-1 were expressed at higher
levels, TGF-β2 and IL-10 expression at lower levels in gliomas from immunized mice than controls. Data reported as peps are mean ± SD of the two
groups of immunized mice.
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effect (possibly caused by deficiency in metabolic flux
from glucose and glutamine to lipids) that is abrogated in
the presence of the hominoid-specific enzyme glutamate
dehydrogenase 2 (GLUD2) [28].
Overall, however, the lethality of pGL261 and mIDH1-
GL261 used in our experiments, was similar. This could
be partly due to the progressive decrease of the frac-
tion of mIDH1-GL261 cells in vivo, as suggested by
decreased 2HG levels detected on day 20 vs day 8
(Figure 2).
Of interest is the increased vascularization and the
hemorrhagic features of mIDH1-GL261 gliomas. Ini-
tial data suggested that reduced formation of alpha-
ketoglutarate (alpha-KG) may increase the levels of
hypoxia-inducible factor subunit HIF-1α [10]. Subse-
quent studies had difficulties in replicating thosefindings [29,30]. Notably, the brain-specific knock-in
of the R132H mutation was associated to hemorrhages
in the presence of increased HIF-1α expression and defi-
cient collagen maturation and basement membrane func-
tion [23].
Despite the low score obtained using the class I MHC
binding prediction we immunized immune competent
IDH1 mutated glioma-bearing mice using four short
peptides (two 9-mers and two 10-mers). A CD8+ T cell
response, specific cytotoxicity and an antibody response
were activated leading to a significant increase of survival.
In particular, specificity was suggested by the lack of
immune response when peptide vaccination took place in
mice bearing parental GL261, lacking the IDH1 mutation.
Immunization with the 16-mer peptide containing MHC
class I and class II epitopes only induced a CD8+ T cells
without antibody response. Survival is significantly higher
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tide immunizations, possibly because of the lack of activa-
tion of the antibody response.
CTL epitopes alone can be inefficient in inducing a
long-term immune response and a specific memory
[31], whereas MHC class I and class II restricted epi-
topes in a single longer peptide can improve vaccine
efficacy based on the simultaneous activation of CTL
and CD4+ T cells [32-34]. This condition was observed
after immunizations with 35 amino-acid long peptides
containing CTL epitopes showed more efficient than
those with CTL peptides in inducing effective anti-tumor
cytotoxic response [35].
A number of reports support the essential role of CD4+
T cells in the anti-tumor responses due to their ability to
stimulate dendritic cells and potentiate anti-tumor im-
mune response by enhancing antigen presentation [36,37]
and to the contribution to the memory response esta-
blishment [38]. Importantly CD4+ T cells have also been
described to develop cytotoxicity and they are able to
eradicate established melanomas [39]. However there is
also evidence that long peptides can modulate the efficacy
of immunization by affecting the magnitude of CTL
response [40,41].
In our experiments we used as immune adjuvants
GM-CSF and Montanide ISA-51, a water-in-oil emul-
sion enhancing the cytotoxic CD8+ T lymphocyte re-
sponse. This was reported in patients [42-44], and was
also supported by our previous pre-clinical experiments,
where immunizations with short peptides induced CD8+
T cell positive activation and tumor specific cytotox-
icity [17,18].
In conclusion, both our data and those of Platten and
coworkers [14] converge in supporting a translational
evolution of immunological targeting of the R132H mu-
tation of IDH1 in glioma patients.
There is increasing clinical evidence that immune
checkpoint inhibitors like ipilimumab and nivolumab
may prolong survival in patients with melanoma and
small cell lung cancer [45,46]. Preclinical evidence
support a role for this therapeutic approach in gli-
omas [47] and a clinical trial is now ongoing to test
this hypothesis. It is plausible that a combination of
this nonspecific form of activation of the immune sys-
tem with specific mutation targeting, as is the case for
the R132H mutation, may yield a synergic effect. This
hypothesis deserves further testing in an appropriate
murine model.Additional files
Additional file 1: Supplementary methods.Additional file 2: Figure S1. mIDH1-GL261 gliomas maintain 2HG
production and are strongly hemorrhagic. Figure S2. Splenocytes from
mice immunized with IDH1-R132H peptides do not lyse pGL261 cells.
Figure S3. Gliomas from immunized mice show a decreased expression
of HIF1-α and VEGF.
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